Roche Signs an Exclusive Worldwide Option and License Agreement with Vividion Focusing on Novel E3 Ligases

Roche Reports Results of Risdiplam in Pivotal SUNFISH Study for Patients with Type 2 or 3 Spinal Muscular Atrophy

Shots:

  • Vividion to receive $135M upfront in cash and is eligible to receive billion dollars preclinical, development and commercial milestones along with royalties on sales of commercialized products resulting from the collaboration
  • Vividion will be responsible for early drug discovery and pre-clinical development for selected programs and has the right to conduct clinical development up to POC with the option to share development costs along with profits and losses with Roche
  • Roche to leverage its proteomics screening platform and proprietary small molecule library to target novel E3 ligases along with the range of oncology and immunology therapeutic targets and has the exclusive right to license resulting compounds at different stages of development

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Roche